Nitric oxide administration using an oxygen hood: a pilot trial.
BACKGROUND
We have shown earlier that inhaled nitric oxide (iNO) administered by oxygen hood reduces pulmonary hypertension in an animal model (J Perinatol 2002; 22:50-6). Our objective in this study was to determine feasibility of iNO by oxygen hood in neonates with elevated alveolar-arterial oxygen gradients (A-aDO(2)).


RESULTS
Masked randomized controlled pilot trial. Inclusion criteria were: gestation>or=34 weeks, age<7 days, with post-ductal arterial line, and A-aDO(2) 400-600. Infants were randomized to study gas (iNO 20 ppm or equivalent O(2) flow) for 1 hr which was then weaned over the next 4 hours. Primary outcome was PaO(2) one hour post-randomization. Four infants each were randomized to iNO or O(2) (controls). Two of the four infants given iNO had an increase in PaO(2) of >100 torr, while oxygenation was unchanged in the controls. Methemoglobinemia and other adverse effects were not noted in any infant. Environmental levels of NO and NO(2) were minimal (<1 ppm) at >0.3 m from the hood.


CONCLUSIONS
Administration of iNO by oxygen hood is feasible. Larger randomized controlled trials are required to measure the efficacy and determine an appropriate target population for this technique.


BACKGROUND
ClinicalTrials.gov NCT00041548.
Ambalavanan
Namasivayam
N
Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, United States of America. ambal@uab.edu
El-Ferzli
George T
GT
Roane
Claire
C
Johnson
Robert
R
Carlo
Waldemar A
WA
D000280:Administration, Inhalation; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000628:therapy; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D009569:Nitric Oxide / Q000008:administration & dosage* / Q000627:therapeutic use; D010100:Oxygen / Q000097:blood; D010102:Oxygen Inhalation Therapy; D010547:Persistent Fetal Circulation Syndrome / Q000628:therapy*
D009569:Nitric Oxide; D010100:Oxygen